PHARMACOGENETICS OF PAROXETINE FOR AUTISM

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这是一项用艾司西酞普兰治疗自闭症谱系障碍儿童的研究。这种药是血清素再摄取抑制剂。这些药物已被发现对这组儿童有帮助。然而，剂量很难预测。因此，我们正在研究血清素系统中的特定基因，看看这些基因是否能预测剂量差异，以及耐受性和疗效的差异。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a study of the treatment of children with autism spectrum disorders with the medication escitalopram. This medication is a serotonin reuptake inhibitor. These medications have been found to be helpful in this group of children. However, the dosing is very difficult to predict. Therefore, we are looking at particular genes in the serotonin system to see if these genes predict for dosing differences, as well as differences in tolerability and efficacy.